Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed?
Damora Therapeutics (DMRA) has seen its stock price rise by 5.1% after initiating the global Phase 1/1b CLARITY-101 trial for its investigational mutCALR-targeting antibody DMR-001. This trial aims to address essential thrombocythemia and myelofibrosis, representing a crucial step towards a potential first mutCALR-targeted therapy. …